Table 2: Adverse Events graded based on CTCAE 4.0.
Apatinib (N=26) |
|||
Adverse Events |
Grade 1/2, n (%) |
Grade 3, n (%) |
Grade 4, n (%) |
Hematologic |
|||
Leukopenia |
8(30.8) |
1(3.8) |
1(3.8) |
Neutropenia |
6(23.1) |
1(3.8) |
− |
Thrombocytopenia |
4(15.4) |
− |
− |
Anemia |
10(38.5) |
2(7.7) |
− |
Non-hematologic |
|||
Proteinuria |
3(11.5) |
− |
− |
Hypertension |
6(23.1) |
1(3.8) |
− |
Bleeding |
2(7.7) |
− |
− |
Esophageal fistula |
− |
1(3.8) |
− |
Fatigue |
6(23.1) |
1(3.8) |
− |
Appetite loss |
9(34.6) |
− |
− |
Nausea |
7(26.9) |
− |
− |
Vomiting |
5(19.2) |
− |
− |
Abdominal pain |
4(15.4) |
− |
− |
Diarrhea |
6(23.1) |
− |
− |
Hand-foot skin reaction |
3(11.5) |
− |
− |
Hypoproteinemia |
3(11.5) |
− |
|
Hypocalcemia |
2(7.7) |
1(3.8) |
− |
Liver function |
|||
Hyperbilirubinemia |
4(15.4) |
− |
− |
Elavated trasaminase |
5(19.2) |
− |
− |
Renal disorder |
|||
Creatinine clearance decrease |
2(7.7) |
− |
− |
Hypothyroidism |
4(15.4) |
1(3.8) |
− |
Others |
|||
Heart failure |
− |
1(3.8) |
− |
CTCAE: Cancer Institute’s Common Terminology Criteria for Adverse Events.